Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ethris and Shire have signed a research deal to develop stable and non-immunogenic messenger RNA (SNIM-RNA) molecules.
Subscribe to our email newsletter
The collaboration will leverage RNA modification technology developed by Ethris and its co-founders, Dr. Carsten Rudolph and Prof. Christian Plank, to produce SNIM-RNA molecules ideal for use in protein replacement therapies.
Financial terms of the transaction were not revealed.
Ethris CSO and co-founder Prof. Christian Plank said the company’s partnership with Shire is based on a shared appreciation of the importance of SNIM technology.
"Under this partnership, we are aiming to develop an RNA modification and delivery technology that efficiently results in protein replacement in relevant cellular populations, providing hope to patients suffering from genetic diseases which have devastating clinical outcomes" Plank added.